Multicomponent mRNA-1083 Vaccine Study

This is a UK news story, published by Nature, that relates primarily to Moderna news.

UK news

For more UK news, you can click here:

more UK news

Moderna news

For more Moderna news, you can click here:

more Moderna news

News about vaccine development

For more vaccine development news, you can click here:

more vaccine development news

Nature news

For more news from Nature, you can click here:

more news from Nature

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about

seasonal influenza vaccine

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest multicomponent vaccine news, influenza vaccine news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

influenza virus vaccines

Nature

•

Health

mRNA-based seasonal influenza and SARS-CoV-2 multicomponent vaccine in healthy adults: a phase 1/2 trial - Nature Medicine

Summary

Nutrition label

86% Informative

mRNA-based multicomponent vaccine (mRNA-1083) encoding seasonal influenza and SARS-CoV-2 antigens.

The vaccine was generally well-tolerated, with most solicited adverse reactions being Grade 1 or 2 in severity.

The incidence of unsolicited adverse events was similar across vaccine groups.

Co-administration of influenza and COVID-19 vaccines: policy review and vaccination coverage trends in the European Union , UK , US , and Canada between 2019 and 2023 .

Moderna announces positive phase 3 efficacy data for mRNA-1283, the company’s next generation.

Fluarix Quadrivalent ( Influenza Vaccine ) injectable suspension, for intramuscular use—20232024. The study was funded by Moderna, Inc. , who had a role in study conceptualization/design, data collection, data analysis, preparation of the manuscript and decision to publish the results.

VR Score

Informative language

Neutral language

Article tone

formal

Language

English

Language complexity

Offensive language

not offensive

Hate speech

not hateful